- Joined
- Sep 19, 2017
- Messages
- 6,172
- Reaction score
- 0
directly to the pharmaceutical industry!
I know this isn't a real shocker for anyone who has been paying attention, but maybe... just maybe, it's time to start rethinking all the chemicals that from birth to grave, people are expected to consume.
The dean of Yale’s medical school, the incoming president of a prominent cancer group and the head of a Texas cancer center are among leading medical figures who have not accurately disclosed their relationships with drug companies.
This story was co-published with The New York Times.
One is dean of Yale’s medical school. Another is the director of a cancer center in Texas. A third is the next president of the most prominent society of cancer doctors.
These leading medical figures are among dozens of doctors who have failed in recent years to report their financial relationships with pharmaceutical and health care companies when their studies are published in medical journals, according to a review by ProPublica and The New York Times and data from other recent research.
Dr. Howard A. “Skip” Burris III, the president-elect of the American Society of Clinical Oncology, for instance, declared that he had no conflicts of interest in more than 50 journal articles in recent years, including in the prestigious New England Journal of Medicine.
However, drug companies have paid his employer nearly $114,000 for consulting and speaking, and nearly $8 million for his research during the period for which disclosure was required. His omissions extended to the Journal of Clinical Oncology, which is published by the group he will lead....
https://www.propublica.org/article/...stry-ties-disclosures-medical-journal-studies
https://www.nytimes.com/2018/12/08/health/medical-journals-conflicts-of-interest.html
I know this isn't a real shocker for anyone who has been paying attention, but maybe... just maybe, it's time to start rethinking all the chemicals that from birth to grave, people are expected to consume.
The dean of Yale’s medical school, the incoming president of a prominent cancer group and the head of a Texas cancer center are among leading medical figures who have not accurately disclosed their relationships with drug companies.
This story was co-published with The New York Times.
One is dean of Yale’s medical school. Another is the director of a cancer center in Texas. A third is the next president of the most prominent society of cancer doctors.
These leading medical figures are among dozens of doctors who have failed in recent years to report their financial relationships with pharmaceutical and health care companies when their studies are published in medical journals, according to a review by ProPublica and The New York Times and data from other recent research.
Dr. Howard A. “Skip” Burris III, the president-elect of the American Society of Clinical Oncology, for instance, declared that he had no conflicts of interest in more than 50 journal articles in recent years, including in the prestigious New England Journal of Medicine.
However, drug companies have paid his employer nearly $114,000 for consulting and speaking, and nearly $8 million for his research during the period for which disclosure was required. His omissions extended to the Journal of Clinical Oncology, which is published by the group he will lead....
https://www.propublica.org/article/...stry-ties-disclosures-medical-journal-studies
https://www.nytimes.com/2018/12/08/health/medical-journals-conflicts-of-interest.html